Summary
The only evaluable prescribing-information claim provided in the input is about overdose/death risk increased with higher doses or unapproved administration methods; this is supported by the VYVANSE boxed warning and Sections 5.1 and 9.2. However, most of the additional listed claims are not prescribing-information-aligned evaluation targets because the supplied label excerpts contain only abuse/misuse warnings and overdose description, not pricing/patent/exclusivity or alternative-treatment claims. Therefore, broader label alignment cannot be confirmed from the provided label text.
Category Scores
Accurate Statements
Risk of overdose and death is increased with higher doses or unapproved methods of administration (e.g., snorting or injection) due to abuse/misuse of VYVANSE.
Supported by VYVANSE Boxed Warning and Sections 5.1 and 9.2: “Misuse and abuse of CNS stimulants... can result in overdose and death... [and] this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.”
Unsupported Statements
In the first half of 2023, the average wholesale price (AWP) of lisdexamfetamine increased by 8.63% to approximately $402 per prescription.
Not supported by the provided VYVANSE label excerpts (which address abuse/misuse and overdose).
In the latter half of 2022, the AWP of lisdexamfetamine increased by 2.43%.
Not supported by the provided VYVANSE label excerpts.
In the first half of 2022, the AWP of lisdexamfetamine increased by 38.51%.
Not supported by the provided VYVANSE label excerpts.
The pricing of lisdexamfetamine is influenced by research and development costs, manufacturing expenses, and market demand.
Not supported by the provided VYVANSE label excerpts.
Lisdexamfetamine is a branded medication with patent protections that contribute to premium pricing.
Not supported by the provided VYVANSE label excerpts.
The original patent for lisdexamfetamine expired in 2023.
Not supported by the provided VYVANSE label excerpts.
A secondary patent related to the formulation extends market exclusivity for the brand-name lisdexamfetamine drug until at least 2027.
Not supported by the provided VYVANSE label excerpts.
The extended protection allows the manufacturer to maintain higher prices without direct competition from generic versions for a longer period.
Not supported by the provided VYVANSE label excerpts.
Generic versions of lisdexamfetamine are contingent upon patent expiry and regulatory approval.
Not supported by the provided VYVANSE label excerpts.
Although the primary patent has expired, the secondary formulation patent has delayed the entry of generics.
Not supported by the provided VYVANSE label excerpts.
Once all relevant patents expire and the U.S. Food and Drug Administration (FDA) approves generic applications, lower-cost alternatives could become available to patients.
Not supported by the provided VYVANSE label excerpts.
Methylphenidate (Ritalin, Concerta) is an alternative medication for treating conditions like ADHD.
Not supported by the provided VYVANSE label excerpts (no indication/dosing/treatment alternatives content shown).
Amphetamine salts (Adderall, Evekeo) are alternatives for treating conditions like ADHD.
Not supported by the provided VYVANSE label excerpts.
Atomoxetine (Strattera) is a non-stimulant option for treating conditions like ADHD.
Not supported by the provided VYVANSE label excerpts.
Guanfacine (Intuniv) is a non-stimulant option for treating conditions like ADHD.
Not supported by the provided VYVANSE label excerpts.
Lisdexamfetamine is sold under the brand name Vyvanse.
The supplied excerpts do not explicitly state this; brand-name mapping is not verifiable from the shown label text.
Contradictions
Important Omissions
No additional dosing/administration, contraindications, boxed warning details beyond abuse/misuse risk, or population-specific safety information were provided in the evaluated AI claims set (except the single supported overdose/death risk statement).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-grounded safety claim provided (increased overdose/death risk with higher doses and unapproved administration methods like snorting/injection) aligns with the boxed warning/Warnings and Precautions. The other claims relate to pricing/patents or alternative drugs and are not supported by the provided label excerpts, but they do not directly introduce a specific labeled safety instruction contradiction within the supplied text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims (pricing/AWP, patent exclusivity, and alternative medication examples) are not supported by the provided VYVANSE label excerpts.
Suggested Improvement
Limit statements to what is verifiable from the supplied label text (e.g., abuse/misuse overdose/death risk with higher doses and unapproved administration methods). Remove or separately source pricing/patent and alternative-treatment claims outside the label excerpts provided.